Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
The Ras Gene02:38

The Ras Gene

6.3K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.3K
Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

9.0K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.0K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

12.3K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.3K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.2K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CNR1 and CNR2 Cannabinoid Receptor Mutations in Cancer Cells.

Current issues in molecular biology·2026
Same author

Cancer mutations in RAD51 and its paralogues.

PloS one·2026
Same author

MS-ConTab: multi-scale contrastive learning of mutation signatures for Pan-Cancer representation and stratification.

Bioinformatics (Oxford, England)·2026
Same author

Nucleotide Substitution Biases in Related Cancer Driver Genes.

International journal of molecular sciences·2025
Same author

Mutations altering the DNA binding domains of the human RAD52 protein exert distinct effects on homologous recombination repair in Saccharomyces cerevisiae.

G3 (Bethesda, Md.)·2025
Same author

PRMT5 genetic interactions with DNA double strand break repair genes.

PloS one·2025

Related Experiment Video

Updated: Aug 3, 2025

Quantitative Methods to Study Protein Arginine Methyltransferase 1-9 Activity in Cells
08:11

Quantitative Methods to Study Protein Arginine Methyltransferase 1-9 Activity in Cells

Published on: August 7, 2021

4.2K

Protein Arginine Methyltransferase 5 (PRMT5) Mutations in Cancer Cells.

Shayaan Rasheed1,2, Renee A Bouley3, Ryan J Yoder3

  • 1James Comprehensive Cancer Center, The Ohio State University Columbus, Columbus, OH 43210, USA.

International Journal of Molecular Sciences
|April 13, 2023
PubMed
Summary

Protein arginine methyltransferase 5 (PRMT5) mutations in cancer were analyzed. Key driver mutations in the active site and non-coding mutations affecting splicing were identified, offering insights for targeted cancer therapies.

Keywords:
arginine methylationcancermutationpost-translational modification

More Related Videos

An In Vitro Assay to Detect tRNA-Isopentenyl Transferase Activity
07:46

An In Vitro Assay to Detect tRNA-Isopentenyl Transferase Activity

Published on: October 8, 2018

7.0K
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.6K

Related Experiment Videos

Last Updated: Aug 3, 2025

Quantitative Methods to Study Protein Arginine Methyltransferase 1-9 Activity in Cells
08:11

Quantitative Methods to Study Protein Arginine Methyltransferase 1-9 Activity in Cells

Published on: August 7, 2021

4.2K
An In Vitro Assay to Detect tRNA-Isopentenyl Transferase Activity
07:46

An In Vitro Assay to Detect tRNA-Isopentenyl Transferase Activity

Published on: October 8, 2018

7.0K
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Arginine methylation, regulated by Protein Arginine Methyltransferase 5 (PRMT5), is a crucial posttranslational modification involved in DNA repair, inflammation, and signal transduction.
  • PRMT5 plays a significant role in DNA double-strand break repair and checkpoint activation, making it a key target in cancer therapy.
  • Small molecule inhibitors targeting PRMT5 enzymatic activity have been developed, highlighting the therapeutic potential of targeting this enzyme.

Purpose of the Study:

  • To analyze and classify somatic mutations in PRMT5 found in cancer cells.
  • To identify driver mutations that may promote cellular transformation.
  • To understand the impact of PRMT5 mutations on enzyme activity and potential therapeutic strategies.

Main Methods:

  • Analysis of PRMT5 mutations from the Catalogue of Somatic Mutations in Cancers (COSMIC) database.
  • Application of artificial intelligence algorithms to classify mutations as drivers or passengers.
  • In silico protein modeling and electrostatic analysis of the enzyme active site.

Main Results:

  • Identification of key driver mutations in the PRMT5 active site (D306H, L315P, N318K) potentially affecting S-adenosylmethionine (SAM) binding affinity.
  • In silico analysis revealed a mutation-induced tunnel near the SAM binding site, suggesting a mechanism for decreased enzyme activity.
  • Discovery of non-coding mutations impacting PRMT5 splicing.

Conclusions:

  • PRMT5 mutations significantly influence its function and role in cancer development.
  • The identified driver mutations provide a deeper understanding of PRMT5's oncogenic potential.
  • This research offers insights into how PRMT5 mutations may affect the efficacy of targeted PRMT5 inhibitors, guiding future therapeutic development.